ERYP News and Press, Erytech Pharma S.A. From 11/05/20

Erytech Pharma (ERYP): 9M net loss of €53.6MCash and cash equivalents of €40.5M.Press Release For further details see: Erytech Pharma reports 9M results

Conference call and webcast on Friday, November 6 at 2:30 pm CET/8:30 am ET TRYbeCA-1 Phase 3 trial in second-line metastatic pancreatic cancer: More than 9 5 % of the approximately 500 patients enrolled Number of events required for the interim super...

Oral presentation to discuss f indings from the Nordic Society of Paediatric Haematology and Oncology ( NOPHO ) - sponsored Phase 2 trial that confirm the potential of e ryaspase as a treatment option ...

ERYTECH Pharma (ERYP) has received approval for  for a total of €10M in non-dilutive financing from Bpifrance and Société Générale in the form of State-Guaranteed Loans in the context of the COVID-19 pandemic.Each of Bpifrance and Socié...

Approvals received from Bpifrance and Société Générale for a total of EUR 10 million in non-dilutive financing in the form of a State- Guarantee d Loan (PGE Loan) Proceeds expected to extend Company’s...

LYON, France, Oct. 29, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris : ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells , t oday announ...

LYON, France and CAMBRIDGE, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced the appo...

ERYTECH is progressing a phase 3 trial in pancreatic cancer. The drug, reformulated L-asparaginase, has known anti-cancer properties but its safety profile needs to be good. If that happens, then this relatively unknown stock could be a profitable investment. For further det...

FN Media Group Presents USA News Group News Commentary Vancouver, BC – October 22, 2020 – USA News Group – It’s been a year and a half since the US Food and Drug Administration approved the first targeted immunotherapy in the treatment...

The following slide deck was published by ERYTECH Pharma S.A. in conjunction with their 2020 Q2 earnings call. For further details see: ERYTECH Pharma S.A. 2020 Q2 - Results - Earnings Call Presentation